Abstract Library

#4346 Efficacy and safety of surufatinib in the treatment of thymic neuroendocrine tumours: A 102-case retrospective study

Introduction: The SANET-ep study confirmed that patients with non-pancreatic NET could benefit from surufatinib treatment compared with placebo. However, there is a lack of sufficient retrospective data on surufatinib’s efficacy in treating thymic neuroendocrine tumours (TNETs).

Conference:

Presenting Author:

Authors: Jia X, Sun Z, Xu J, Huang D, Chen F,

Keywords: neuroendocrine tumour, thymic, surufatinib, treatment,

#4148 S-1/temozolomide versus S-1/temozolomide plus thalidomide in advanced pancreatic and non-pancreatic neuroendocrine tumors (STEM): A randomised, open-label, multicentre phase 2 trial

Introduction: There are currently limited systemic treatment options for patients with advanced neuroendocrine tumors (NETS) and the efficacy of existing treatments is sub-optimal.

Conference:

Presenting Author:

Authors: Chi Y, Song L, Liu W, Zhou Y, Miao Y,

Keywords: S-1, temozolomide, thalidomide, neuroendocrine tumor,

#3822 68Ga-DOTA peptides PET/CT radiomics in differentiation between pancreatic NET from physiologic uncinate process uptake

Introduction: 68Ga-DOTA peptides PET/CT (PET/CT) is the gold standard for neuroendocrine tumors detection (NET), which are often localized in the pancreas. Physiological uptake of pancreatic uncinate process (UP) is a known false positive site in almost of patients.

Conference:

Presenting Author: Linguanti F

Authors: Linguanti F, Abenavoli E, Briganti V, Mungai F, Antonuzzo L,

Keywords: 68Ga-Dota peptide, PET/CT, pancreas, neuroendocrine tumor, pNET,

#3687 Lutetium-177 DOTATATE PRRT versus PRRT plus chemotherapy in metastatic well differentiated FDG-avid GEP-NETs – Results from a prospective cohort

Introduction: Combination therapy with PRRT and Capecitabine-Temozolomide (CAPE-TMZ) has benefited patients with FDG avid well-differentiated GEP-NETs.

Conference:

Presenting Author:

Authors: Puranik A, Rangarajan V, Shrikhande S, Ramaswamy A, Ostwal V,

Keywords: PRRT, capecitabine, temozolomide, FDG PET, DOTA PET,

#2299 Expanding the WHO 2017 Classification to Gastrointestinal Tumors: Real-World Data from the R-GETNE Registry

Introduction: The update of the WHO 2017 classification of pancreatic neuroendocrine tumors (NETs) introduces the distinction between NET & NEC G3, based on histological differentiation. However, little is known about the possibility of extending this concept to non-pancreatic NETs.

Conference: 15th Annual ENETSConcerence (2018)

Presenting Author:

Authors: Carmona-Bayonas A, Jimenez-Fonseca P, Castaño A, Capdevila J, Benavent M,

Keywords: WHO classification, NET G3, NEC G3, non-pancreatic NET, poorly differentiated,